Loading XRAY detail
Loading ticker data...
Loading XRAY detail
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide.
The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed clear aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products. The Consumables segment offers endodontic products comprising drills, filers, sealers, irrigation needles, and other tools or single-use solutions, which support root canal procedures; restorative products that include artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. It also provides small equipment products, which comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride.
The company was founded in 1877 and is headquartered in Charlotte, North Carolina.
Chart data unavailable
DENTSPLY SIRONA Inc. (NASDAQ: XRAY - Get Free Report) has been assigned an average rating of "Hold" from the fifteen research firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating
XRAY bets on digital workflows and R&D expansion to fuel growth, but forex pressure and weak Europe demand cloud its near-term outlook.
Gregory Lucier acquired 15,000 shares for a total of approximately ~$187,000 on March 9, 2026. No direct holdings were involved in the transaction; all shares are held indirectly via trusts or similar entities.
Dentsply Sirona and Siemens Healthineers win FDA clearance for the first dental-dedicated MRI designed to improve soft-tissue dental imaging and diagnostics.
DENTSPLY SIRONA Inc. (XRAY) Presents at Leerink Global Healthcare Conference 2026 Transcript
A handful of the industry's income-generating gems are hiding in plain sight.
Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI 1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial 2 validating the system's significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology's applicability in endodontics, periodontics, TMJ, tooth extraction, and orthodontics, offering non-ionizing imaging capabilities that can enhance diagnosis and treatment planning.
Shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY - Get Free Report) fell 7.5% during trading on Friday. The stock traded as low as $12.31 and last traded at $12.33. 662,151 shares were traded during mid-day trading, a decline of 87% from the average session volume of 4,911,188 shares. The stock had previously closed at $13.33.
CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 10, 2026, at 10:00 a.m. EST.
Review Dentsply's (XRAY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
XRAY climbs nearly 8% pre-market as it unveils a $120M restructuring plan, even after Q4 earnings miss and softer 2026 outlook.
DENTSPLY SIRONA Inc. (XRAY) Q4 2025 Earnings Call Transcript
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Dentsply International (XRAY) came out with quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.26 per share a year ago.
